18F-Fluciclovine PET-MRI in High-grade Glioma
Recruiting · Early phase 1 · NCT05553041
Conditions: Glioma, High Grade Glioma, Glioma, Malignant, Glioma Intracranial, Diffuse Glioma
At a glance
- Research payments reported, 2025
- $5,166
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 30
About the trial
- Sponsor
- Children's Hospital of Philadelphia (with Blue Earth Diagnostics, Dragon Master Foundation)
- Tested
- 18F-Fluciclovine PET-MRI (drug)
- Dates
- Started 2024-08-07; completion 2027-12
- Results posted
- Not yet
The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.
From ClinicalTrials.gov, last updated 2025-12-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $5,166 in research payments for this study in 2025 (1 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.